Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS

Abstract

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes with different progression rates, varying degree of extra-motor involvement and divergent progression patterns. The natural history of ALS is increasingly evaluated by large, multi-time point longitudinal studies, many of which now incorporate presymptomatic and post-mortem assessments. These studies not only have the potential to characterize patterns of anatomical propagation, molecular mechanisms of disease spread, but also to identify pragmatic monitoring markers. Sensitive markers of progressive neurodegenerative change are indispensable for clinical trials and individualized patient care. Biofluid markers, neuroimaging indices, electrophysiological markers, rating scales, questionnaires, and other disease-specific instruments have divergent sensitivity profiles. The discussion of candidate monitoring markers in ALS has a dual academic and clinical relevance, and is particularly timely given the increasing number of pharmacological trials. The objective of this paper is to provide a comprehensive and critical review of longitudinal studies in ALS, focusing on the sensitivity profile of established and emerging monitoring markers.

Introduction

Amyotrophic lateral sclerosis (ALS) is a clinically, genetically, and pathologically heterogeneous neurodegenerative condition (1–3). Clinical heterogeneity in ALS is multidimensional owing to variations in upper motor neuron (UMN) and lower motor neuron (LMN) involvement, extra-motor symptoms, age of onset, survival, and progression-rates. Disease heterogeneity hinders biomarker development (3, 4) which in turn impedes the reliable assessment of candidate drugs in clinical trials (1). Current clinical trials recruit relatively heterogeneous cohorts of symptomatic patients, despite the notion that considerable pathological changes can already be detected at the time of diagnosis (5, 6). The considerable variability in progression rates in ALS is another confounding factor in clinical trial designs (1, 7–10). Imaging and electrophysiological markers have been repeatedly proposed as candidate monitoring markers (11, 12), but it is increasingly clear that a panel of several “wet” and “dry” biomarkers may be required to capture subtle changes over short periods of time (13, 14). The objective of this paper is the comprehensive and critical review of longitudinal studies in ALS, focusing on study designs, statistical power, clinical correlations, the sensitivity profile of proposed monitoring markers and their applicability to clinical trials.

Methods

A formal literature search was performed on PubMed using the core search terms “amyotrophic lateral sclerosis” and “longitudinal” combined with each of the following keywords separately: “staging,” “monitoring,” “outcomes,” “clinical,” “clinical trials,” “electrophysiology,” “neurophysiology,” “electromyography,” “transcranial magnetic stimulation,” “motor unit number estimation,” “motor unit number index,” “positon emission tomography,” “single photon emission computed tomography,” “magnetic resonance imaging,” “neuroimaging,” “imaging,” “blood,” “urine,” “cerebrospinal fluid,” “saliva,” and “muscle.” A supplementary search combined the core search terms with the following keywords: “presymptomatic,” “asymptomatic,” and “post-mortem.” Inclusion criteria included longitudinal studies investigating imaging, neurophysiological, clinical, or biofluid biomarkers in ALS. Animal studies, review papers, opinion pieces, editorials, case reports, and case series were excluded. Only articles written in English and published between January 1980 and August 2018 were reviewed. Based on the above criteria a total of 118 original research papers were selected and reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.

Results

Neuroimaging

The sample size characteristics, study design features, follow-up intervals of longitudinal neuroimaging, neurophysiology, and clinical studies are summarized in Table 1. Whilst most longitudinal imaging studies in ALS evaluate cerebral alterations (10), a number of promising spinal studies have now also been published. Spinal imaging has gradually overcome the technical challenges of physiological motion, small cross-sectional dimensions and susceptibility gradients (19, 110–118). The majority of longitudinal studies in ALS are single-center studies eliminating the need for cross-platform MR sequence harmonization and inter-rater reliability tests. Given the low incidence of certain phenotypes such as primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and spinal and bulbar muscular atrophy (SBMA) however, multisite collaboration is often necessary (119). The infrastructure, funding and governance of such multicenter collaborations are now established via international consortia like the Neuroimaging Society in Amyotrophic Lateral Sclerosis (NISALS) or the Northeast ALS Consortium (NEALS) (16, 23, 120, 121). The need to include disease-controls in addition to healthy controls to describe ALS-specific changes is increasingly recognized (30, 43, 44). With few exceptions (122–124), most ALS imaging studies use 3 Tesla platforms and 7 Tesla systems are more commonly used in post-mortem studies (125, 126). Disease progression has been detected across a range of MR imaging metrics including structural (22, 26), diffusion (16, 18), functional (28, 40), and spectroscopy (41, 42) measures. As the majority of studies have a two-timepoint design, it is often unclear if specific imaging metrics show linear or exponential changes. The few existing multi-timepoint studies suggest that pathological change is not linear (10). The revised ALS functional rating scale (ALSFRS-r) is the most commonly reported clinical measure (16, 18–20), with only few imaging studies reporting associations with staging (15) or neuropsychological performance (15, 24).

Neurophysiology

Most longitudinal neurophysiology studies are single center studies, reducing the risk of inter-rater and inter-center variability (127). As presented in Table 1, follow-up interval ranges between 7 days (65) and 3 years (66), and up to 7 follow-up time-points have been included in some studies (57, 60). Surprisingly few studies include disease controls such as peripheral neuropathy (60) or benign fasciculation syndrome (50). Clinical assessments performed in conjunction with neurophysiology typically include ALSFRS-r (51), forced vital capacity (FVC) (55), slow vital capacity (SVC) (56), grip strength (64), pinch strength (58), and manual muscle testing (MMT) (58), however, correlations between neurophysiological measures and clinical assessments are seldom reported. The majority of longitudinal neurophysiological studies focus on upper limb muscles, e.g., abductor pollicis brevis, deltoid, first dorsal interrosseus, extensor digitorum brevis, abductor digiti minimi (51, 52, 55, 60, 61) with relatively few studies evaluating lower limb muscles such as abductor hallicus brevis and tibialis anterior (50, 56, 57, 66). The most commonly reported longitudinal neurophysiological indices include compound muscle action potential (CMAP) (51, 52), single motor unit action potential (SMUAP) (60), MUNE (55, 59), MUNIX (49, 56), neurophysiology index (NI) (54, 55), TMS measures (57, 58), and axonal excitability (52). Progressive neurophysiological changes have been detected by MUNIX (49, 51, 56), MUNE (51, 58, 60), CMAP (52, 61), NI (54), and TMS measures (57) and allowing for study-design limitations, the consensus is that degenerative changes are not linear.

Clinical Biomarkers and Instruments

Robust clinical longitudinal studies in ALS have up to 6 follow-up time points (88, 89, 91), the interval between the assessments can be as short as 3 months (95) and the sample size can be as big as several thousands (70, 93) (Table 1). Few multi-timepoint studies include disease controls such as motor neuropathies (91), alternative neuromuscular diseases (78), or neurodegenerative conditions (83). Large, multi-timepoint longitudinal studies invariably suffer from considerable attrition rates, but these are rarely explicitly reported in the manuscript abstracts (10). Detailed genotyping is only available in a minority of longitudinal studies (15, 77, 79, 94). The most widely utilized rating scale in longitudinal studies is the ALSFRS-r (70, 71, 128) which provides a composite score of bulbar, limb and respiratory dysfunction, and is invariably evaluated in clinical trials (72, 105). Quality of life (QoL) in ALS is increasingly evaluated by disease-specific instruments such as the 40-item ALS assessment questionnaire (ALSAQ-40) or the revised ALS-specific Quality of Life questionnaire (ALSSQoL-R) (129–131). A number of symptom-specific instruments are also commonly used such as the Center for Neurologic Study-Bulbar Function Scale (CNS-BFS), a 21-item self-report scale of bulbar function, and the Center for Neurologic Study-Lability Scale (CNS-LS), a 7-item self-report scale of pseudobulbar affect (PBA) (132). Tapping rates, composite reflex scores, The Penn UMN Score (133), the Modified Ashworth scale (MAS) are often used as proxies of UMN degeneration (132).

In clinical trials, muscle strength is often estimated by handheld dynamometry (HHD) (134), manual muscle testing (MMT) (105), scoring systems such as the Medical Research Council (MRC) Scale for muscle strength (135) and some studies also report limb circumference (136). Respiratory function in ALS is typically monitored by sniff nasal inspiratory pressure (SNIP), SVC, or FVC in addition to measures such as early morning arterial blood gas (ABG) and overnight pulse-oximetry (137, 138). Measures of typing ability (91), tongue movements (90), vital capacity (VC) (96), FVC (99), SNIP (97), and diaphragm amplitude (97) all show progressive longitudinal changes. Nutritional markers such as body mass index (BMI) and lipid profile are now established prognostic indicators (139, 140). Cognitive and behavioral domains are routinely assessed thanks to the availability of validated screening instruments such as the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) (141), the Beaumont Behavioral Inventory (BBI) (142) and the ALS Cognitive Behavioral Screen (ALS-CBS) (143). In contrast to the relentlessly progressive motor deficits of ALS, the trajectory of cognitive and behavioral deficits is less clear due to considerable individual variations, genotype-associated profiles (144, 145), differences in assessment strategies and practice-effects (146). Several longitudinal neuropsychology studies do not detect progression (77, 147, 148), progressive behavioral impairment has been noted in the absence of cognitive change (149), and some studies report improved performance as a result of practice effects (77).

Wet Biomarkers

The findings, study design characteristics, and follow-up intervals of longitudinal biofluid studies are summarized in Table 2. Phosphorylated neurofilament heavy chain (pNFH), neurofilament light chain (NF-L), progranulin (PGRN), cytokines, TAR DNA-binding protein 43 (TDP-43), cystatin C, creatinine, micro-RNAs (miRNAs), chitotriosidase-1 (CHIT1), chitinase-3-like protein 1 (CHI3L1), chitinase-3-like protein 2 (CHI3L2) have been evaluated in both research studies (152, 153, 157, 158, 162, 164, 168, 171) and clinical trials (150, 156, 157, 160, 161). Markers of iron metabolism and ferroptosis are relatively recent domains of ALS biomarker research (172, 173). Most biofluid studies are either serum (150, 157) or CSF studies (152, 167), but urine (155) and skeletal muscle-based (153) studies have now also been published. Quantitative enzyme-linked immunosorbent assay (ELISA) is the most commonly used antibody-based technique (13, 174) which can be performed with one antibody (indirect ELISA), or with two antibodies (sandwich ELISA). Increased CSF (13) and serum (175) pNFH detected by ELISA is thought to be a sensitive marker of axonal degeneration in ALS (152, 171, 176, 177). The specificity of this marker however may be inadequate to reliably differentiate ALS from other neurodegenerative conditions (13, 176). Other antibody-based techniques such as Western blot (171) and electrochemiluminescence (ECL) (153, 168) may improve detection sensitivity and reliability (13). Panels of multiple proteins can be evaluated by multiplex immunoassays such as planar or microbead assays (13). Mass spectrometry based methods using chromatin-immunoprecipitation-based surfaces, two-dimensional gel electrophoresis or high-resolution mass spectrometry have identified cystatin-C and transthyretin as candidate biomarkers (178–180). The longest wet biomarker study followed patients for 4 years (164). The majority of studies have at least 2 follow-up timepoints (155, 162, 170) and one study included 13 follow-up timepoints (156, 159). Large multi-center trials include as much as 1,000 participants (156). One of the most striking shortcomings of existing longitudinal studies is that very few included disease controls such as Parkinson's disease cohorts, patients with multifocal motor neuropathy with conduction block, Kennedy's disease, chronic inflammatory demyelinating polyneuropathy (CIDP), cervical or lumbar radiculopathy, Charcot-Marie-Tooth disease (CMT), benign fasciculation, and cramp syndrome etc. (152, 159, 162). Another limitation of many longitudinal studies is the lack of comprehensive genotyping (12) as very few studies report comprehensive screening for ALS-associated mutations (153, 159, 169, 171). Exhaustive clinical profiling, such as medications (152, 164), neuropsychological assessments (171), quality of life indices are rarely reported in longitudinal studies. The majority of studies limit their clinical descriptions to ALSFRS-r, FVC, MRC, and Ashworth scores (153, 161, 162). Serum and plasma biomarkers such as creatinine (150, 156), pNfH (158, 159), and micro-RNAs (157), CSF biomarkers such as CHI3L1 (152), tau (160, 161), and cystatin-C (162), and urinary (155) and skeletal muscle (153) biomarkers are some of the promising tools for detecting disease progression. While no progressive changes have been detected in NFL levels, it is likely to be a useful as a diagnostic biomarker (168, 171).

Studies of Asymptomatic Mutation Carriers

Current clinical trials only recruit symptomatic cases despite accruing evidence that ALS has a long presymptomatic phase (5). Imaging studies of asymptomatic mutation carriers have consistently confirmed disease-specific cerebral and spinal cord changes prior to symptom onset (181–184) indicating that this disease-phase may represent a crucial window for therapeutic or neuroprotective intervention. The majority of presymptomatic studies assess a single time-point, as opposed to the longitudinal tracking of asymptomatic carriers of ALS-causing mutations (15). While the overwhelming majority of presymptomatic studies focus on C9orf72 hexanucleotide carriers (183, 185–187), no prognostic markers have been validated to predict whether single patients will develop ALS or FTD. Compared to imaging studies, strikingly few presymptomatic neurophysiology studies have been undertaken (66). Studies of asymptomatic ALS-causing mutation carriers have enormous potential for academic research and may pave the way for asymptomatic pharmaceutical trials (5, 181).

Discussion

Clinical trials currently evaluate the efficacy of candidate drugs using the revised ALS functional rating scale (ALSFRS-r), muscle strength assessment tools such as manual muscle testing (MMT), respiratory function indices such as forced vital capacity (FVC), slow vital capacity (SVC) and sniff nasal inspiratory pressure (SNIP), neurophysiological measures and survival (102, 116, 120, 188, 189). These measures however primarily reflect late-stage functional impairment and are not indicative of early stage pathology. Brain and spinal cord imaging has been evaluated as early-stage biomarkers with both diagnostic and monitoring potential (116, 120, 190). The core neuroimaging signature of ALS, irrespective of the disease-stage, includes corticospinal tract (191, 192), corpus callosum (193) and motor cortex degeneration (194). Atrophy in frontotemporal regions has been primarily associated with neuropsychological deficits (195–197) and linked to hexanucleotide repeats in C9orf72 (145, 198). Longitudinal imaging studies are superior to cross-sectional studies as they readily detect dynamic structural and functional changes and may elucidate compensatory processes (10, 14, 23, 28, 40, 120, 199). The emergence of multi-timepoint study designs (14, 20) enable the characterization of anatomical propagation patterns (200) and provide invaluable temporal insights into the disease trajectory of late-stage ALS. Inter-scan intervals as short as 3 months can detect longitudinal changes (14, 18, 120). Many longitudinal studies make use of multiple magnetic resonance (MR) metrics which is particularly useful in establishing an optimal panel of monitoring markers (120). Several longitudinal studies have indicated that white matter degeneration can be detected relatively early in the course of ALS with restricted further progression over time, whereas gray matter pathology shows relentless progression in the symptomatic phase of the disease (4, 14, 120). In addition to structural imaging studies, connectivity-based, metabolic, peripheral nerve, and, whole body muscle imaging have contributed to our understanding of longitudinal changes (20, 201–203).

Needle electromyography and nerve conduction studies play an important clinical role in ruling out alternative conditions and confirming a suspected diagnosis of ALS. Despite variations in local protocols, neurophysiological tests are recognized as objective, reliable and cost-effective tests of neuromuscular dysfunction, and have also been repeatedly proposed as longitudinal markers (55, 204). CMAP is generated by depolarization of muscle fibers through the stimulation of a single nerve, where amplitude reductions are interpreted as loss of motor axons (205, 206). While CMAP measurements capture longitudinal decline, it is confounded by variations in temperature, limb positioning and electrode placement (56, 207). CMAP-derived measures such as MUNE and MUNIX are now extensively utilized to characterize progressive changes in ALS. MUNE estimates motor neuron numbers, and may detect the rate of motor neuron loss, making it a more reliable method of appraising disease progression than CMAP (208, 209). However, its early-phase sensitivity has been questioned, as its use is limited to distal muscles, and the technique requires considerable training, especially for inter-rater and multi-site comparisons (205, 210). TMS allows the characterization of upper motor neuron dysfunction, and may be particularly useful in detecting progressive changes (57, 205).

Functional rating-scales are often the monitoring instruments of choice in clinical trials (55), as they are easy to administer, cost-effective to utilize and have acceptable inter- and intra-rater reliability profiles (7). The most widely used rating scale in clinical longitudinal studies is the ALSFRS-r. Despite its ease of administration, it has considerable limitations, as it may be disproportionately influenced by LMN dysfunction, does not account for laterality or asymmetry of symptoms, omits cognitive impairment, and may be affected by medications (14, 128, 188, 211).

Proteomics, metabolomics and lipidomics have seen significant advances in ALS research and CSF and serum markers are now used in longitudinal academic and pharmacological studies (172). Potential biomarkers for the detection of disease progression include serum and plasma biomarkers such as creatinine (150, 156), pNfH (158, 159), and micro-RNAs (157), CSF biomarkers such as CHI3L1 (152), tau (160, 161), and cystatin-C (162), and urinary (155) and skeletal muscle (153) biomarkers.

Prediction Analyses

Age at symptom onset (212), BMI (139), bulbar involvement (213), cognitive impairment (214), C9orf72 genotype status (144), respiratory insufficiency (215), “definite ALS” by the El Escorial criteria (216), and functional disability (217) are the most commonly cited determinants of poor prognosis in ALS. SNIP (218) and less commonly used measures such as twitch trans-diaphragmatic pressure (Tw Pdi) (219) and maximal static expiratory mouth pressure (MEP) were shown to be good predictors of ventilator-free survival (219). A combined panel of several clinical, wet, and dry biomarkers is likely to offer the most accurate prognostic information (115, 120, 216, 217, 220). While cerebral (217, 221, 222) and spinal (115) imaging measures have been repeatedly linked to survival outcomes, these have not been utilized in a clinical setting. Neurophysiological variables, such as phrenic nerve stimulation outcomes (223) and biofluid markers, such as pNFH and NFL (165, 168, 224–226) are also thought to be accurate predictors.

Patient Stratification

Attempts to enroll patients in the early stages of the disease are hampered by the universally long diagnostic delay in ALS (227). Patient stratification in trials is typically based on site of onset (228), instead of other variables which have an established prognostic impact (138, 229). Admixed patient cohorts within a trial may hamper the ability to detect how different phenotypes and genotypes may exhibit a different response to a candidate drug (230–232). The stratification of heterogeneous cohorts is now aided by the development of validated staging systems, such as the King's (233), Milano-Torino (MITOS) (234) or the Fine'til 9 (FT9) (235) staging systems. The King's Staging system is based on the number of body regions affected, and the presence of nutritional or respiratory failure (233). The MITOS staging system is based on the ALSFRS-r, and is particularly sensitive to changes in later stages of the disease (236, 237). However, none of these staging systems account for cognitive or behavioral changes (236). Pathological staging systems suggest a four-stage model of ALS based on anatomical patterns of pTDP-43 load (238, 239). This system has now been validated by in vivo neuroimaging studies (240) and signals that accurate pathological staging and patient stratification may be possible based on neuroimaging (199, 240).

International Consortia

Only few ALS centers maintain dedicated biobanking facilities to store and process molecular markers in human biofluid locally. Similarly, relatively few centers are in a position to generate sufficient number of MRI and neurophysiology data sets of rare phenotypes to make meaningful inferences in a single center setting. Brain and tissue banks are also challenging to establish, maintain and fund, despite their invaluable contribution to ALS research (241–243).

Biospecimen samples are also often collected during clinical trials, and discarded after negative outcomes, despite their enormous potential for biomarker discovery (172). One of the most important achievements of biomarker development efforts is the establishment of national and international research consortia such as Association pour la recherche sur la SLA (ARSLA), Neuroimaging Society in ALS (NISALS), Research Motor Neuron (RMN), Canadian ALS Neuroimaging Consortium (CALSNIC), EU Joint Programme for Neurodegenerative Disease Research (JPND), European multidisciplinary ALS network identification to cure motor neurone degeneration (EUROMOTOR) which maintain vital biobanking facilities, registries, data repositories for multicenter data interpretation (121, 244). Clinical trial networks are also increasingly recognized as valuable platforms for multisite data collection and interpretation as they operate with carefully standardized protocols. Consortia such as the European Registry of ALS (EURALS) Consortium, the Western ALS (WALS) Consortium and the Northeast ALS (NEALS) Consortium are other examples (245). NEALS is one of the largest consortia with over 100 member sites from the US, Canada, Mexico, Italy, Lebanon and Australia (246). EURALS coordinates research studies and clinical trials relying on population-based European registries and include centers from Scotland, England, Netherlands, Spain, Ireland, Serbia, Italy, France, and Germany (241, 247, 248). ALS research consortia promote patient-oriented research, maintain biofluid, imaging and DNA banks, and have the potential to translate scientific advances into pragmatic clinical interventions.

Telehealth

Novel trends in longitudinal data collection include telemedicine-based technologies, wearable sensors and mobile phone applications (230). The continuous collection of data via telephone or telemedicine applications such as the Telehealth in Motor Neuron disease (TiM) system circumvent the inconvenience of patients and caregivers traveling long distances for research appointments (249). Once local data-protection and governance guidelines are complied with, information uploaded from these systems can be made available to healthcare professionals of multidisciplinary teams in real time (249). The feasibility of telehealth for ALS patients via live video-conferencing has also been evaluated (250) and is considered a particularly promising clinical and research platform (249, 250). A number of cognitive-behavioral screening tools have also been adapted for phone administration (251) including modified versions of the ALS Cognitive Behavior Screen (ALS-CBS), the Controlled Oral Word Association Test (COWAT), the Center for Neurologic Study-Lability Scale (CNS-LS) and found to be statistically equivalent to face-to-face assessments (251). Performance on other tests however, such as the telephone versions of the ALS-Frontal Behavioral Inventory (ALS-FBI) caregiver interview and the Written Verbal Fluency Index (WVFI) was not equivalent to clinic-based assessments (251). The continued development of telephone and internet-enabled devices are likely to provide further insights to longitudinal physical, cognitive and behavioral changes (251).

Conclusions

While clinical indicators of disease progression remain indispensable, neuroimaging, neurophysiology, and biofluid measures are particularly promising, objective, quantitative biomarker candidates. The validation of combined “wet” and “dry” biomarker panels will not only enable the detection of subtle progressive changes in ALS, but allow precision stratification of heterogeneous patient cohorts in clinical trials and improve existing prediction algorithms.

References

• 1.

  KatyalNGovindarajanR. Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol. (2017) 8:521. 10.3389/fneur.2017.00521

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  Miller. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. (2002) 14:CD001447. 10.1002/14651858.CD001447

  • CrossRef
  • Google Scholar

• 3.

  Al-ChalabiAJonesATroakesCKingAAl-SarrajSvan den BergLH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. (2012) 124:339–52. 10.1007/s00401-012-1022-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  MenkeRAKornerSFilippiniNDouaudGKnightSTalbotKet al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. (2014) 137(Pt 9):2546–55. 10.1093/brain/awu162

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  EisenAKiernanMMitsumotoHSwashM. Amyotrophic lateral sclerosis: a long preclinical period?J Neurol Neurosurg Psychiatry. (2014) 85:1232–8. 10.1136/jnnp-2013-307135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  BenatarMWuuJ. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. (2012) 79:1732–9. 10.1212/WNL.0b013e31826e9b1d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  MitsumotoHBrooksBRSilaniV. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?Lancet Neurol. (2014) 13:1127–38. 10.1016/S1474-4422(14)70129-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  BeghiEChioACouratierPEstebanJHardimanOLogroscinoGet al. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. (2011) 12:1–10. 10.3109/17482968.2010.502940

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  de CarvalhoMSwashM. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?Arch Neurol. (2006) 63:557–60. 10.1001/archneur.63.4.557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  SchusterCElaminMHardimanOBedeP. Presymptomatic and longitudinal neuroimaging in neurodegeneration–from snapshots to motion picture: a systematic review. J Neurol Neurosurg Psychiatry. (2015) 86:1089–96. 10.1136/jnnp-2014-309888

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  TurnerMRAgostaFBedePGovindVLuleDVerstraeteE. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med. (2012) 6:319–37. 10.2217/bmm.12.26

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  BedePHardimanO. Lessons of ALS imaging: pitfalls and future directions - a critical review. NeuroImage Clin. (2014) 4:436–43. 10.1016/j.nicl.2014.02.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  BowserRTurnerMRShefnerJ. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. (2011) 7:631–8. 10.1038/nrneurol.2011.151

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  BedePHardimanO. Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:232–41. 10.1080/21678421.2017.1407795

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  FloeterMKDanielianLEBraunLEWuT. Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry. (2018) 89:53–60. 10.1136/jnnp-2017-316799

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  KassubekJMullerHPDel TrediciKLuleDGorgesMBraakHet al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. (2018) 89:374–81. 10.1136/jnnp-2017-316365

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  StampfliPSommerSCzellDKozerkeSNeuwirthCWeberMet al. Investigation of neurodegenerative processes in amyotrophic lateral sclerosis using white matter fiber density. Clin Neuroradiol. (2018). 10.1007/s00062-018-0670-8. [Epub ahead of print].

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  BaldaranovDKhomenkoAKoborIBogdahnUGorgesMKassubekJet al. Longitudinal diffusion tensor imaging-based assessment of tract alterations: an application to amyotrophic lateral sclerosis. Front Hum Neurosci. (2017) 11:567. 10.3389/fnhum.2017.00567

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  de AlbuquerqueMBrancoLMRezendeTJde AndradeHMNucciAFrancaMCJr. Longitudinal evaluation of cerebral and spinal cord damage in Amyotrophic Lateral Sclerosis. NeuroImage Clin. (2017) 14:269–76. 10.1016/j.nicl.2017.01.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  MenkeRALProudfootMTalbotKTurnerMR. The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. Neuroimage Clin. (2018) 17:953–61. 10.1016/j.nicl.2017.12.025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  SimonNGLagopoulosJPalingSPflugerCParkSBHowellsJet al. Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. J Neurol. (2017) 264:882–90. 10.1007/s00415-017-8443-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  FloeterMKBageacDDanielianLEBraunLETraynorBJKwanJY. Longitudinal imaging in C9orf72 mutation carriers: relationship to phenotype. NeuroImage Clin. (2016) 12:1035–43. 10.1016/j.nicl.2016.10.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  SchulthessIGorgesMMullerHPLuleDDel TrediciKLudolphACet al. Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis. Sci Rep. (2016) 6:38391. 10.1038/srep38391

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  McMillanCTRussJWoodEMIrwinDJGrossmanMMcCluskeyLet al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology. (2015) 84:1622–30. 10.1212/WNL.0000000000001495

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  SteinbachRLoeweKKaufmannJMachtsJKolleweKPetriSet al. Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography. J Neurol. (2015) 262:2257–70. 10.1007/s00415-015-7841-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  WestenengH-JVerstraeteEWalhoutRSchmidtRHendrikseJVeldinkJHet al. Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging. (2015) 36:1075–82. 10.1016/j.neurobiolaging.2014.09.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  SchusterCKasperEMachtsJBittnerDKaufmannJBeneckeRet al. Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol. (2014) 261:1871–80. 10.1007/s00415-014-7426-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  StoppelCMVielhaberSEckartCMachtsJKaufmannJHeinzeHJet al. Structural and functional hallmarks of amyotrophic lateral sclerosis progression in motor- and memory-related brain regions. NeuroImage Clin. (2014) 5:277–90. 10.1016/j.nicl.2014.07.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  VerstraeteEVeldinkJHvan den BergLHvan den HeuvelMP. Structural brain network imaging shows expanding disconnection of the motor system in amyotrophic lateral sclerosis. Hum Brain Mapp. (2014) 35:1351–61. 10.1002/hbm.22258

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  IgnjatovicAStevicZLavrnicSDakovicMBacicG. Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. J Magn Reson Imaging. (2013) 38:1472–9. 10.1002/jmri.24121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  KwanJYMeodedADanielianLEWuTFloeterMK. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin. (2012) 2:151–60. 10.1016/j.nicl.2012.12.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  KeilCPrellTPeschelTHartungVDenglerRGrosskreutzJ. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. (2012) 13:141. 10.1186/1471-2202-13-141

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  MenkeRAAbrahamIThielCSFilippiniNKnightSTalbotKet al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol. (2012) 69:1493–9. 10.1001/archneurol.2012.1122

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  IchikawaHOhnoHMurakamiHOhnakaYKawamuraM. Writing error may be a predictive sign for impending brain atrophy progression in amyotrophic lateral sclerosis: a preliminary study using X-ray computed tomography. Eur Neurol. (2011) 65:346–51. 10.1159/000328216

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  van der GraaffMMSageCACaanMWAkkermanEMLaviniCMajoieCBet al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain. (2011) 134(Pt 4):1211–28. 10.1093/brain/awr016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  ZhangYSchuffNWoolleySCChiangGCBoretaLLaxamanaJet al. Progression of white matter degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging study. Amyotroph Lateral Scler. (2011) 12:421–9. 10.3109/17482968.2011.593036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  AgostaFGorno-TempiniMLPaganiESalaSCaputoDPeriniMet al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: a tensor based morphometry study. Amyotroph Lateral Scler. (2009) 10:168–74. 10.1080/17482960802603841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  AgostaFRoccaMAValsasinaPSalaSCaputoDPeriniMet al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. (2009) 80:53–5. 10.1136/jnnp.2008.154252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  AvantsBKhanAMcCluskeyLElmanLGrossmanM. Longitudinal cortical atrophy in amyotrophic lateral sclerosis with frontotemporal dementia. Arch Neurol. (2009) 66:138–9. 10.1001/archneurol.2008.542

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  LuleDDiekmannVKassubekJKurtABirbaumerNLudolphACet al. Cortical plasticity in amyotrophic lateral sclerosis: motor imagery and function. Neurorehabil Neural Repair. (2007) 21:518–26. 10.1177/1545968307300698

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  UnrathALudolphACKassubekJ. Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol. (2007) 254:1099–106. 10.1007/s00415-006-0495-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  SuhyJMillerRGRuleRSchuffNLichtJDronskyVet al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI. Neurology. (2002) 58:773–9. 10.1212/WNL.58.5.773

  • CrossRef
  • Google Scholar

• 43.

  BlockWKaritzkyJTräberFPohlCKellerEMundegarRRet al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. (1998) 55:931–6. 10.1001/archneur.55.7.931

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  IrwinDJMcMillanCTBrettschneiderJLibonDJPowersJRascovskyKet al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2013) 84:163–9. 10.1136/jnnp-2012-303507

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  KolindSSharmaRKnightSJohansen-BergHTalbotKTurnerMR. Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:562–73. 10.3109/21678421.2013.794843

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  VerstraeteEVeldinkJHHendrikseJSchelhaasHJvan den HeuvelMPvan den BergLH. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2012) 83:383–8. 10.1136/jnnp-2011-300909

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  BlainCRWilliamsVCJohnstonCStantonBRGanesalingamJJaroszJMet al. A longitudinal study of diffusion tensor MRI in ALS. Amyotroph Lateral Scler. (2007) 8:348–55. 10.1080/17482960701548139

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  RuleRRSuhyJSchuffNGelinasDFMillerRGWeinerMW. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Motor Neuron Disord. (2004) 5:141–9. 10.1080/14660820410017109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  Escorcio-BezerraMLAbrahaoASantos-NetoDde Oliveira BragaNIOliveiraASBManzanoGM. Why averaging multiple MUNIX measures in the longitudinal assessment of patients with ALS?Clin Neurophysiol. (2017) 128:2392–6. 10.1016/j.clinph.2017.09.104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  de CarvalhoMSwashM. Fasciculation potentials and earliest changes in motor unit physiology in ALS. J Neurol Neurosurg Psychiatry. (2013) 84:963–8. 10.1136/jnnp-2012-304545

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51.

  BoekesteinWASchelhaasHJvan PuttenMJStegemanDFZwartsMJvan DijkJP. Motor unit number index (MUNIX) versus motor unit number estimation (MUNE): a direct comparison in a longitudinal study of ALS patients. Clin Neurophysiol. (2012) 123:1644–9. 10.1016/j.clinph.2012.01.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  CheahBCLinCSParkSBVucicSKrishnanAVKiernanMC. Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol. (2012) 123:2460–7. 10.1016/j.clinph.2012.06.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  AhnS-WKimJ-ESungJ-JLeeK-WHongY-H. Asymmetry of motor unit number estimate and its rate of decline in patients with amyotrophic lateral sclerosis. J Clin Neurophysiol. (2011) 28:528–32. 10.1097/WNP.0b013e318231c9e0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54.

  CheahBCVucicSKrishnanAVBolandRAKiernanMC. Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler. (2011) 12:33–8. 10.3109/17482968.2010.531742

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55.

  de CarvalhoMSwashM. Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: a six-month longitudinal study. Muscle Nerve. (2010) 41:208–11. 10.1002/mus.21495

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56.

  NeuwirthCNandedkarSStalbergEWeberM. Motor unit number index (MUNIX): a novel neurophysiological technique to follow disease progression in amyotrophic lateral sclerosis. Muscle Nerve. (2010) 42:379–84. 10.1002/mus.21707

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57.

  FloydAGYuQPPiboolnurakPTangMXFangYSmithWAet al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology. (2009) 72:498–504. 10.1212/01.wnl.0000341933.97883.a4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58.

  GoochCLPullmanSLShunguDCUlugAMChanSGordonPHet al. Motor unit number estimation (MUNE) in diseases of the motor neuron: utility and comparative analysis in a multimodal biomarker study. Suppl Clin Neurophysiol. (2009) 60:153–62. 10.1016/S1567-424X(08)00015-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59.

  LiuXXZhangJZhengJYZhangSXuYSKangDXet al. Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. (2009) 39:304–9. 10.1002/mus.21144

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60.

  AlbrechtEKuntzerT. Number of Edb motor units estimated using an adapted multiple point stimulation method: normal values and longitudinal studies in ALS and peripheral neuropathies. Clin Neurophysiol. (2004) 115:557–63. 10.1016/j.clinph.2003.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  WangFCBouquiauxODe PasquaVDelwaidePJ. Changes in motor unit numbers in patients with ALS: a longitudinal study using the adapted multiple point stimulation method. Amyotroph Lateral Scler Other Motor Neuron Disord. (2002) 3:31–8. 10.1080/146608202317576516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62.

  ChanKMStashukDWBrownWF. A longitudinal study of the pathophysiological changes in single human thenar motor units in amyotrophic lateral sclerosis. Muscle Nerve. (1998) 21:1714–23.

  • Pubmed Abstract
  • Google Scholar

• 63.

  FeliceKJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. (1997) 20:179–85.

  • Pubmed Abstract
  • Google Scholar

• 64.

  YuenECOlneyRK. Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology. (1997) 49:573–8. 10.1212/WNL.49.2.573

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65.

  VucicSLinCSCheahBCMurrayJMenonPKrishnanAVet al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. (2013) 136(Pt 5):1361–70. 10.1093/brain/awt085

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66.

  AggarwalANicholsonG. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry. (2002) 73:199–201. 10.1136/jnnp.73.2.199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67.

  ArasakiKKatoYHyodoAUshijimaRTamakiM. Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve. (2002) 25:520–6. 10.1002/mus.10067

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68.

  de CarvalhoMMirandaPCLuisMLDucla-SoaresE. Cortical muscle representation in amyotrophic lateral sclerosis patients: changes with disease evolution. Muscle Nerve. (1999) 22:1684–92.

  • Pubmed Abstract
  • Google Scholar

• 69.

  SwashMSchwartzMS. A longitudinal study of changes in motor units in motor neuron disease. J Neurol Sci. (1982) 56:185–97. 10.1016/0022-510X(82)90141-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70.

  ThakoreNJLapinBRPioroEP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. (2018) 57:937–45. 10.1002/mus.26042

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  RooneyJBurkeTVajdaAHeverinMHardimanO. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2016) 88:381–5. 10.1136/jnnp-2016-314661

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72.

  The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. (1996) 53:141–7. 10.1001/archneur.1996.00550020045014

  • CrossRef
  • Google Scholar

• 73.

  FloeterMKTraynorBJFarrenJBraunLETierneyMWiggsEAet al. Disease progression in C9orf72 mutation carriers. Neurology. (2017) 89:234–41. 10.1212/WNL.0000000000004115

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74.

  ElaminMBedePByrneSJordanNGallagherLWynneBet al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. (2013) 80:1590–7. 10.1212/WNL.0b013e31828f18ac

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75.

  Roberts-SouthAFindlaterKStrongMJOrangeJB. Longitudinal changes in discourse production in amyotrophic lateral sclerosis. Semin Speech Lang. (2012) 33:79–94. 10.1055/s-0031-1301165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76.

  DuningTSchiffbauerHWarneckeTMohammadiSFloelAKolpatzikKet al. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS ONE. (2011) 6:e17770. 10.1371/journal.pone.0017770

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77.

  PolettiBSolcaFCarelliLFainiAMadottoFLafronzaAet al. Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:387–95. 10.1080/21678421.2018.1473443

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78.

  XuZAlruwailiARSHendersonRDMcCombePA. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci. (2017) 376:16–23. 10.1016/j.jns.2017.02.061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79.

  GillinghamSMYunusovaYGandaARogaevaEBlackSEStussDTet al. Assessing cognitive functioning in ALS: a focus on frontal lobe processes. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:182–92. 10.1080/21678421.2016.1248977

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80.

  MioshiEHsiehSCagaJRamseyEChenKLilloPet al. A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:298–304. 10.3109/21678421.2014.896927

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81.

  Jakobsson LarssonBOzanneAGNordinKNygrenI. A prospective study of quality of life in amyotrophic lateral sclerosis patients. Acta Neurol Scand. (2017) 136:631–8. 10.1111/ane.12774

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82.

  BeckMGiessRMagnusTPulsIReinersKToykaKVet al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2002) 73:68–70. 10.1136/jnnp.73.1.68

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83.

  GarrutoRMPlatoCCYanagiharaRFoxKDuttJGajdusekDCet al. Bone mass in Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Am J Phys Anthropol. (1989) 80:107–13. 10.1002/ajpa.1330800112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84.

  IoannidesZASteynFJHendersonRDMcCombePANgoST. Anthropometric measures are not accurate predictors of fat mass in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:486–91. 10.1080/21678421.2017.1317811

  • CrossRef
  • Google Scholar

• 85.

  PeterRSRosenbohmADupuisLBrehmeTKassubekJRothenbacherDet al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. (2017) 32:901–8. 10.1007/s10654-017-0318-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86.

  NunesGSantosCAGrunhoMFonsecaJ. Enteral feeding through endoscopic gastrostomy in amyotrophic lateral sclerosis patients. Nutr Hosp. (2016) 33:561. 10.20960/nh.561

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87.

  JableckiCKBerryCLeachJ. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. (1989) 12:833–41. 10.1002/mus.880121008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88.

  AndresPLAllredMPStephensHEProffitt BunnellMSienerCMacklinEAet al. Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. (2017) 56:710–5. 10.1002/mus.25586

  • CrossRef
  • Google Scholar

• 89.

  de BieEOskarssonBJoyceNCNicoriciAKurilloGHanJJ. Longitudinal evaluation of upper extremity reachable workspace in ALS by Kinect sensor. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:17–23. 10.1080/21678421.2016.1241278

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90.

  ShellikeriSGreenJRKulkarniMRongPMartinoRZinmanLet al. Speech movement measures as markers of bulbar disease in amyotrophic lateral sclerosis. J Speech Lang Hear Res. (2016) 59:887–99. 10.1044/2016_JSLHR-S-15-0238

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91.

  LondralAPintoSde CarvalhoM. Markers for upper limb dysfunction in Amyotrophic Lateral Sclerosis using analysis of typing activity. Clin Neurophysiol. (2016) 127:925–31. 10.1016/j.clinph.2015.06.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92.

  PanitzSKornhuberMHanischF. The checklist individual strength (CIS20-R) in patients with amyotrophic lateral sclerosis - a longitudinal study. Acta Neurol Scand. (2015) 131:372–80. 10.1111/ane.12349

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93.

  AtassiNBerryJShuiAZachNShermanASinaniEet al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. (2014) 83:1719–25. 10.1212/WNL.0000000000000951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94.

  WatanabeHAtsutaNNakamuraRHirakawaAWatanabeHItoMet al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:230–6. 10.3109/21678421.2014.990036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95.

  LeonardisLDolenc GroseljLVidmarG. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. (2012) 19:1518–24. 10.1111/j.1468-1331.2012.03754.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96.

  MahajanKRBachJRSaporitoLPerezN. Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve. (2012) 46:851–5. 10.1002/mus.23663

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97.

  PintoSGeraldesRVazNPintoAde CarvalhoM. Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol. (2009) 120:2082–5. 10.1016/j.clinph.2009.08.025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98.

  MontesJChengBDiamondBDoorishCMitsumotoHGordonPH. The Timed Up and Go test: predicting falls in ALS. Amyotroph Lateral Scler. (2007) 8:292–5. 10.1080/17482960701435931

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99.

  VenderRLMaugerDWalshSAlamSSimmonsZ. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler. (2007) 8:36–41. 10.1080/17482960600863951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100.

  WilsonSRQuantzMAStrongMJAhmadD. Increasing peak expiratory flow time in amyotrophic lateral sclerosis. Chest. (2005) 127:156–60. 10.1378/chest.127.1.156

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101.

  PoloniMMentoSAMascherpaCCeroniM. Value of spirometric investigations in amyotrophic lateral sclerosis. Ital J Neurol Sci. (1983) 4:39–46. 10.1007/BF02043436

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102.

  AndersenTMSandnesAFondenesONilsenRMTysnesOBHeimdalJHet al. Laryngeal responses to mechanically assisted cough in progressing amyotrophic lateral sclerosis. Respir Care. (2018) 63:538–49. 10.4187/respcare.05924

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103.

  QuarantaVNCarratuPDamianiMFDragonieriSCapozzoloACassanoAet al. The prognostic role of obstructive sleep apnea at the onset of amyotrophic lateral sclerosis. Neurodegener Dis. (2017) 17:14–21. 10.1159/000447560

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104.

  ProudfootMMenkeRASharmaRBernaCMHicksSLKennardCet al. Eye-tracking in amyotrophic lateral sclerosis: a longitudinal study of saccadic and cognitive tasks. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 17:101–11. 10.3109/21678421.2015.1054292

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105.

  LengletTLacomblezLAbitbolJLLudolphAMoraJSRobberechtWet al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. (2014) 21:529–36. 10.1111/ene.12344

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106.

  YamauchiRImaiTTsudaEHozukiTYamamotoDShimohamaS. Respiratory insufficiency with preserved diaphragmatic function in amyotrophic lateral sclerosis. Intern Med. (2014) 53:1325–31. 10.2169/internalmedicine.53.2326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107.

  MendozaMGelinasDFMooreDHMillerRG. A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2007) 8:106–11. 10.1080/17482960601030188

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108.

  Marti-FabregasJDouradoMSanchisJMiraldaRPradasJIllaI. Respiratory function deterioration is not time-linked with upper-limb onset in amyotrophic lateral sclerosis. Acta Neurol Scand. (1995) 92:261–4. 10.1111/j.1600-0404.1995.tb01699.x

  • CrossRef
  • Google Scholar

• 109.

  PalmowskiAJostWHPrudloJOsterhageJKasmannBSchimrigkKet al. Eye movement in amyotrophic lateral sclerosis: a longitudinal study. Ger J Ophthalmol. (1995) 4:355–62.

  • Pubmed Abstract
  • Google Scholar

• 110.

  El MendiliMMChenRTiretBVillardNTrunetSPelegrini-IssacMet al. Fast and accurate semi-automated segmentation method of spinal cord MR images at 3T applied to the construction of a cervical spinal cord template. PLoS ONE. (2015) 10:e0122224. 10.1371/journal.pone.0122224

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111.

  Cohen-AdadJEl MendiliMMMorizot-KoutlidisRLehericySMeiningerVBlanchoSet al. Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:30–8. 10.3109/17482968.2012.701308

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112.

  BedePBokdeALByrneSElaminMFaganAJHardimanO. Spinal cord markers in ALS: diagnostic and biomarker considerations. Amyotroph Lateral Scler. (2012) 13:407–15. 10.3109/17482968.2011.649760

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113.

  El MendiliMMCohen-AdadJPelegrini-IssacMRossignolSMorizot-KoutlidisRMarchand-PauvertVet al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS ONE. (2014) 9:e95516. 10.1371/journal.pone.0095516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114.

  QuerinGEl MendiliMMBedePDelphineSLengletTMarchand-PauvertVet al. Multimodal spinal cord MRI offers accurate diagnostic classification in ALS. J Neurol Neurosurg Psychiatry. (2018) 89:1220–1. 10.1136/jnnp-2017-317214

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115.

  QuerinGEl MendiliMMLengletTDelphineSMarchand-PauvertVBenaliHet al. Spinal cord multi-parametric magnetic resonance imaging for survival prediction in amyotrophic lateral sclerosis. Eur J Neurol. (2017) 24:1040–6. 10.1111/ene.13329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116.

  GrolezGMoreauCDanel-BrunaudVDelmaireCLopesRPradatPFet al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. (2016) 16:155. 10.1186/s12883-016-0672-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117.

  StromanPWWheeler-KingshottCBaconMSchwabJMBosmaRBrooksJet al. The current state-of-the-art of spinal cord imaging: methods. NeuroImage. (2014) 84:1070–81. 10.1016/j.neuroimage.2013.04.124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118.

  VermaTCohen-AdadJ. Effect of respiration on the B0 field in the human spinal cord at 3T. Magn Reson Med. (2014) 72:1629–36. 10.1002/mrm.25075

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119.

  FineganEChipikaRHShingSLHHardimanOBedeP. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?Amyotroph Lateral Scler Frontotemporal Degener.2019:1–13. 10.1080/21678421.2018.1550518

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120.

  BedePQuerinGPradatPF. The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools. Curr Opin Neurol. (2018) 31:431–8. 10.1097/WCO.0000000000000569

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121.

  MullerHPTurnerMRGrosskreutzJAbrahamsSBedePGovindVet al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2016) 87:570–9. 10.1136/jnnp-2015-311952

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122.

  AtassiNXuMTriantafyllouCKeilBLawsonRCernasovPet al. Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. PLoS ONE. (2017) 12:e0177680. 10.1371/journal.pone.0177680

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123.

  VerstraeteEBiesselsGJvan Den HeuvelMPVisserFLuijtenPRvan Den BergLH. No evidence of microbleeds in ALS patients at 7 Tesla MRI. Amyotroph Lateral Scler. (2010) 11:555–7. 10.3109/17482968.2010.513053

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124.

  DimondDIshaqueAChenjiSMahDChenZSeresPet al. White matter structural network abnormalities underlie executive dysfunction in amyotrophic lateral sclerosis. Hum Brain Mapp. (2017) 38:1249–68. 10.1002/hbm.23452

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125.

  CardenasAMSarllsJEKwanJYBageacDGalaZSDanielianLEet al. Pathology of callosal damage in ALS: an ex-vivo, 7 T diffusion tensor MRI study. NeuroImage Clin. (2017) 15:200–8. 10.1016/j.nicl.2017.04.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126.

  De ReuckJDevosDMoreauCAugerFDurieuxNDeramecourtVet al. Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. Acta Neurol Belg. (2017) 117:873–8. 10.1007/s13760-017-0832-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127.

  PugdahlKFuglsang-FrederiksenAJohnsenBTankisiHde CarvalhoMFawcettPRWet al. Variation in the neurophysiological examination of amyotrophic lateral sclerosis in Europe. Amyotroph Lateral Scler. (2010) 11:443–8. 10.3109/17482960903552496

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128.

  CedarbaumJMStamblerNMaltaEFullerCHiltDThurmondBet al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. (1999) 169:13–21.

  • Pubmed Abstract
  • Google Scholar

• 129.

  PetrovDMansfieldCMoussyAHermineO. ALS clinical trials review: 20 Years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. (2017) 9:68. 10.3389/fnagi.2017.00068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130.

  JenkinsonCHarrisRFitzpatrickR. The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40): evidence for a method of imputing missing data. Amyotroph Lateral Scler. (2007) 8:90–5. 10.1080/17482960600989343

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131.

  AggarwalSPZinmanLSimpsonEMcKinleyJJacksonKEPintoHet al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology. (2010) 9:481–8. 10.1016/S1474-4422(10)70068-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132.

  SmithRPioroEMyersKSirdofskyMGoslinKMeekinsGet al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. (2017) 14:762–72. 10.1007/s13311-016-0508-5

  • CrossRef
  • Google Scholar

• 133.

  WooJHWangSMelhemERGeeJCCucchiaraAMcCluskeyLet al. Linear associations between clinically assessed upper motor neuron disease and diffusion tensor imaging metrics in amyotrophic lateral sclerosis. PLoS ONE. (2014) 9:e105753. 10.1371/journal.pone.0105753

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134.

  CudkowiczMETitusSKearneyMYuHShermanASchoenfeldDet al. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurology. (2014) 13:1083–91. 10.1016/S1474-4422(14)70222-4

  • CrossRef
  • Google Scholar

• 135.

  BensimonGLacomblezLMeiningerV. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. (1994) 330:585–91. 10.1056/NEJM199403033300901

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136.

  KimSKimJKSonMJKimDSongBSonIet al. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. Trials. (2018) 19:225. 10.1186/s13063-018-2557-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137.

  ShefnerJMLiuDLeitnerMLSchoenfeldDJohnsDRFergusonTet al. Quantitative strength testing in ALS clinical trials. Neurology. (2016) 87:617–24. 10.1212/WNL.0000000000002941

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138.

  BerryJDPaganoniSAtassiNMacklinEAGoyalNRivnerMet al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. (2017) 56:1077–84. 10.1002/mus.25733

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139.

  JawaidAMurthySBWilsonAMQureshiSUAmroMJWheatonMet al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. (2010) 11:542–8. 10.3109/17482968.2010.482592

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140.

  CalvoAMogliaCLunettaCMarinouKTicozziNFerranteGDet al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. (2017) 264:54–63. 10.1007/s00415-016-8313-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141.

  AbrahamsSNewtonJNivenEFoleyJBakTH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:9–14. 10.3109/21678421.2013.805784

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142.

  ElaminMPinto-GrauMBurkeTBedePRooneyJO'SullivanMet al. Identifying behavioural changes in ALS: validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. (2016) 8:68–73. 10.1080/21678421.2016.1248976

  • CrossRef
  • Google Scholar

• 143.

  WoolleySCYorkMKMooreDHStruttAMMurphyJSchulzPEet al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler. (2010) 11:303–11. 10.3109/17482961003727954

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144.

  ByrneSElaminMBedePShatunovAWalshCCorrBet al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. (2012) 11:232–40. 10.1016/S1474-4422(12)70014-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145.

  BedePBokdeALWByrneSElaminMMcLaughlinRLKennaKet al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. (2013) 81:361–9. 10.1212/WNL.0b013e31829c5eee

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146.

  ChristidiFKaravasilisERentzosMKelekisNEvdokimidisIBedeP. Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis. Front Neurol. (2018) 9:1005. 10.3389/fneur.2018.01005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147.

  BurkhardtCNeuwirthCWeberM. Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): lack of practice effect in ALS patients?Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:202–9. 10.1080/21678421.2017.1283418

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148.

  KasperEZydatissKSchusterCMachtsJBittnerDKaufmannJet al. No change in executive performance in ALS patients: a longitudinal neuropsychological study. Neurodegener Dis. (2016) 16:184–91. 10.1159/000440957

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149.

  WoolleySGoetzRFactor-LitvakPMurphyJHupfJLomen-HoerthCet al. Longitudinal screening detects cognitive stability and behavioral deterioration in ALS patients. Behav Neurol. (2018) 2018:5969137. 10.1155/2018/5969137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150.

  OkadaMYamashitaSUeyamaHIshizakiMMaedaYAndoY. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. (2018) 11:11–4. 10.1016/j.ensci.2018.05.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151.

  RahejaRRegevKHealyBCMazzolaMABeynonVVon GlehnFet al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. (2018) 58:261–9. 10.1002/mus.26106

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152.

  ThompsonAGGrayEThezenasMLCharlesPDEvettsSHuMTet al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. (2018) 83:258–68. 10.1002/ana.25143

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153.

  Di PietroLBaranziniMBerardinelliMGLattanziWMonforteMTascaGet al. Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients. Sci Rep. (2017) 7:9538. 10.1038/s41598-017-10161-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154.

  MurdockBJZhouTKashlanSRLittleRJGoutmanSAFeldmanEL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. (2017) 74:1446–54. 10.1001/jamaneurol.2017.2255

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155.

  ShepheardSRWuuJCardosoMWiklendtLDinningPGChatawayTet al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. (2017) 88:1137–43. 10.1212/WNL.0000000000003741

  • CrossRef
  • Google Scholar

• 156.

  van EijkRPAEijkemansMJCFergusonTANikolakopoulosSVeldinkJHvan den BergLH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. (2018) 89:156–61. 10.1136/jnnp-2017-317077

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157.

  WallerRGoodallEFMiloMCooper-KnockJDa CostaMHobsonEet al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. (2017) 55:123–31. 10.1016/j.neurobiolaging.2017.03.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158.

  McCombePAPflugerCSinghPLimCYAireyCHendersonRD. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. (2015) 353:122–9. 10.1016/j.jns.2015.04.032

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159.

  LuCHPetzoldAToppingJAllenKMacdonald-WallisCClarkeJet al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. (2015) 86:565–73. 10.1136/jnnp-2014-307672

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160.

  LevineTDBowserRHankNCGatelySStephanDSapersteinDSet al. A pilot trial of pioglitazone HCl and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of disease progression. Neurol Res Int. (2012) 2012:582075. 10.1155/2012/582075

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161.

  LevineTDBowserRHankNSapersteinD. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. (2010) 11:514–9. 10.3109/17482968.2010.513052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162.

  WilsonMEBoumazaILacomisDBowserR. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE. (2010) 5:e15133. 10.1371/journal.pone.0015133

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163.

  GaianiAMartinelliIBelloLQuerinGPuthenparampilMRuggeroSet al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. (2017) 74:525–32. 10.1001/jamaneurol.2016.5398

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164.

  LuCHAllenKOeiFLeoniEKuhleJTreeTet al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. (2016) 3:e244. 10.1212/NXI.0000000000000244

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165.

  SteinackerPFenebergEWeishauptJBrettschneiderJTumaniHAndersenPMet al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. (2016) 87:12–20. 10.1136/jnnp-2015-311387

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166.

  GibsonSBKasarskisEJHuNPulstSMMendiondoMSMatthewsDEet al. Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:473–7. 10.3109/21678421.2015.1062516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167.

  GrayELarkinJRClaridgeTDTalbotKSibsonNRTurnerMR. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:456–63. 10.3109/21678421.2015.1053490

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168.

  LuCHMacdonald-WallisCGrayEPearceNPetzoldANorgrenNet al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. (2015) 84:2247–57. 10.1212/WNL.0000000000001642

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169.

  VerstraeteEKuiperijHBvan BlitterswijkMMVeldinkJHSchelhaasHJvan den BergLHet al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2012) 13:446–51. 10.3109/17482968.2012.703208

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170.

  NardoGPozziSPignataroMLauranzanoESpanoGGarbelliSet al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE. (2011) 6:e25545. 10.1371/journal.pone.0025545

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171.

  SteinackerPHussAMayerBGrehlTGrosskreutzJBorckGet al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:112–9. 10.1080/21678421.2016.1241279

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172.

  BlascoHPatinFDescatAGarconGCorciaPGelePet al. A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression. PLoS ONE. (2018) 13:e0198116. 10.1371/journal.pone.0198116

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173.

  MasaldanSBushAIDevosDRollandASMoreauC. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. (2018) 133:221–33. 10.1016/j.freeradbiomed.2018.09.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174.

  Van WeemenBKSchuursAH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. (1971) 15:232–6. 10.1016/0014-5793(71)80319-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175.

  BoylanKYangCCrookJOverstreetKHeckmanMWangYet al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. (2009) 111:1182–91. 10.1111/j.1471-4159.2009.06386.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176.

  ReijnTSAbdoWFSchelhaasHJVerbeekMM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. (2009) 256:615–9. 10.1007/s00415-009-0131-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177.

  StrongMJKesavapanySPantHC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?J Neuropathol Exp Neurol. (2005) 64:649–64. 10.1097/01.jnen.0000173889.71434.ea

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178.

  RanganathanSWilliamsEGanchevPGopalakrishnanVLacomisDUrbinelliLet al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. (2005) 95:1461–71. 10.1111/j.1471-4159.2005.03478.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179.

  RybergHAnJDarkoSLustgartenJLJaffaMGopalakrishnanVet al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. (2010) 42:104–11. 10.1002/mus.21683

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180.

  PasinettiGMUngarLHLangeDJYemulSDengHYuanXet al. Identification of potential CSF biomarkers in ALS. Neurology. (2006) 66:1218. 10.1212/01.wnl.0000203129.82104.07

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181.

  MenkeRAProudfootMWuuJAndersenPMTalbotKBenatarMet al. Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. J Neurol Neurosurg Psychiatry. (2016) 87:580–8. 10.1136/jnnp-2015-311945

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182.

  CarewJDNairGAndersenPMWuuJGronkaSHuXet al. Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology. (2011) 77:1370–5. 10.1212/WNL.0b013e318231526a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183.

  LeeSESiasACMandelliMLBrownJABrownABKhazenzonAMet al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin. (2017) 14:286–97. 10.1016/j.nicl.2016.12.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184.

  NgMCHoJTHoSLLeeRLiGChengTSet al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging. (2008) 27:8–13. 10.1002/jmri.21217

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185.

  WenJZhangHAlexanderDCDurrlemanSRoutierARinaldiDet al. Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry. (2018). 10.1136/jnnp-2018-318994. [Epub ahead of print].

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186.

  BertrandAWenJRinaldiDHouotMSayahSCamuzatAet al. Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 Years. JAMA Neurol. (2018) 75:236–45. 10.1001/jamaneurol.2017.4266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187.

  PapmaJMJiskootLCPanmanJLDopperEGden HeijerTDonker KaatLet al. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. (2017) 89:1256–64. 10.1212/WNL.0000000000004393

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188.

  KolleweKMaussUKrampflKPetriSDenglerRMohammadiB. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. (2008) 275:69–73. 10.1016/j.jns.2008.07.016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189.

  RudnickiSABerryJDIngersollEArchibaldDCudkowiczMEKerrDAet al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14:44–51. 10.3109/17482968.2012.723723

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190.

  BedePIyerPMFineganEOmerTHardimanO. Virtual brain biopsies in amyotrophic lateral sclerosis: diagnostic classification based on in vivo pathological patterns. NeuroImage Clin. (2017) 15:653–8. 10.1016/j.nicl.2017.06.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191.

  BedePElaminMByrneSMcLaughlinRLKennaKVajdaAet al. Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry. (2015) 86:468–70. 10.1136/jnnp-2014-308172

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192.

  SchusterCElaminMHardimanOBedeP. The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration. Eur J Neurol. (2016) 23:1361–71. 10.1111/ene.13038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193.

  FilippiniNDouaudGMackayCEKnightSTalbotKTurnerMR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. (2010) 75:1645–52. 10.1212/WNL.0b013e3181fb84d1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194.

  BedePBokdeAElaminMByrneSMcLaughlinRLJordanNet al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. (2013) 84:766–73. 10.1136/jnnp-2012-302674

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195.

  ChristidiFKaravasilisEZalonisIFerentinosPGiavriZWildeEAet al. Memory-related white matter tract integrity in amyotrophic lateral sclerosis: an advanced neuroimaging and neuropsychological study. Neurobiol Aging. (2017) 49:69–78. 10.1016/j.neurobiolaging.2016.09.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196.

  BedePElaminMByrneSMcLaughlinRLKennaKVajdaAet al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology. (2013) 81:2107–15. 10.1212/01.wnl.0000437313.80913.2c

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197.

  BedePOmerTFineganEChipikaRHIyerPMDohertyMAet al. Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging Behav. (2018) 12:1696–707. 10.1007/s11682-018-9837-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198.

  AgostaFFerraroPMRivaNSpinelliEGDomiTCarreraPet al. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. (2017) 57:206–19. 10.1016/j.neurobiolaging.2017.05.024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199.

  BedePIyerPMSchusterCElaminMMcLaughlinRLKennaKet al. The selective anatomical vulnerability of ALS: 'disease-defining' and 'disease-defying' brain regions. Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:561–70. 10.3109/21678421.2016.1173702

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200.

  RavitsJMLa SpadaAR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. (2009) 73:805–11. 10.1212/WNL.0b013e3181b6bbbd

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201.

  LoeweKMachtsJKaufmannJPetriSHeinzeHJBorgeltCet al. Widespread temporo-occipital lobe dysfunction in amyotrophic lateral sclerosis. Sci Rep. (2017) 7:40252. 10.1038/srep40252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202.

  JenkinsTMAlixJJPDavidCPearsonERaoDGHoggardNet al. Imaging muscle as a potential biomarker of denervation in motor neuron disease. J Neurol Neurosurg Psychiatry. (2018) 89:248–55. 10.1136/jnnp-2017-316744

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203.

  JongbloedBAHaakmaWGoedeeHSBosJWBosCHendrikseJet al. Comparative study of peripheral nerve Mri and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. (2016) 54:1133–5. 10.1002/mus.25391

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204.

  de CarvalhoMChioADenglerRHechtMWeberMSwashM. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler. (2005) 6:17–28. 10.1080/14660820410020600

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205.

  RutkoveSB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. (2015) 12:384–93. 10.1007/s13311-014-0331-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206.

  KimuraJ. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. Oxford: Oxford University Press (2001).

  • Google Scholar

• 207.

  LeweltAKrosschellKJScottCSakonjuAKisselJTCrawfordTOet al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve. (2010) 42:703–8. 10.1002/mus.21838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208.

  NandedkarSDNandedkarDSBarkhausPEStalbergEV. Motor unit number index (MUNIX). IEEE Trans Biomed Eng. (2004) 51:2209–11. 10.1109/TBME.2004.834281

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209.

  McComasAJFawcettPRCampbellMJSicaRE. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry. (1971) 34:121–31. 10.1136/jnnp.34.2.121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210.

  NeuwirthCBraunNClaeysKGBucelliRFournierCBrombergMet al. Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: real world experience from 27 centres. Clin Neurophysiol. (2018) 129:1756–62. 10.1016/j.clinph.2018.04.614

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211.

  FastenauPSDenburgNLMauerBA. Parallel short forms for the Boston Naming Test: psychometric properties and norms for older adults. J Clin Exp Neuropsychol. (1998) 20:828–34. 10.1076/jcen.20.6.828.1105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212.

  ZoccolellaSBeghiEPalaganoGFraddosioAGuerraVSamarelliVet al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. (2008) 79:33–7. 10.1136/jnnp.2007.118018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 213.

  ChioALogroscinoGHardimanOSwinglerRMitchellDBeghiEet al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. (2009) 10:310–23. 10.3109/17482960802566824

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214.

  ElaminMPhukanJBedePJordanNByrneSPenderNet al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. (2011) 76:1263–9. 10.1212/WNL.0b013e318214359f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215.

  MagnusTBeckMGiessRPulsINaumannMToykaKV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. (2002) 25:709–14. 10.1002/mus.10090

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216.

  WestenengHJDebrayTPAVisserAEvan EijkRPARooneyJPKCalvoAet al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. (2018) 7:423–33. 10.1016/S1474-4422(18)30089-9

  • CrossRef
  • Google Scholar

• 217.

  SchusterCHardimanOBedeP. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. (2017) 17:73. 10.1186/s12883-017-0854-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218.

  CapozzoRQuarantaVNPellegriniFFontanaACopettiMCarratuPet al. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol. (2015) 262:593–603. 10.1007/s00415-014-7613-3

  • CrossRef
  • Google Scholar

• 219.

  PolkeyMILyallRAYangKJohnsonELeighPNMoxhamJ. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. (2017) 195:86–95. 10.1164/rccm.201604-0848OC

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220.

  GordonPHSalachasFLacomblezLLe ForestierNPradatPFBruneteauGet al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis. (2013) 12:81–90. 10.1159/000341316

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221.

  KalraSVitaleACashmanNRGengeAArnoldDL. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2006) 77:1253–5. 10.1136/jnnp.2006.090696

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222.

  AgostaFPaganiEPetroliniMSormaniMPCaputoDPeriniMet al. MRI predictors of long-term evolution in amyotrophic lateral sclerosis. Eur J Neurosci. (2010) 32:1490–6. 10.1111/j.1460-9568.2010.07445.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223.

  PintoSPintoAde CarvalhoM. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol. (2012) 123:2454–9. 10.1016/j.clinph.2012.05.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224.

  PijnenburgYAVerweyNAvan der FlierWMScheltensPTeunissenCE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (2015) 1:505–12. 10.1016/j.dadm.2015.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225.

  OberstadtMClassenJArendtTHolzerM. TDP-43 and cytoskeletal proteins in ALS. Mol Neurobiol. (2018) 55:3143–51. 10.1007/s12035-017-0543-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 226.

  GanesalingamJAnJShawCEShawGLacomisDBowserR. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. (2011) 117:528–37. 10.1111/j.1471-4159.2011.07224.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227.

  PaganoniSMacklinEALeeAMurphyAChangJZipfAet al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:453–6. 10.3109/21678421.2014.903974

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228.

  CudkowiczMEvan den BergLHShefnerJMMitsumotoHMoraJSLudolphAet al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology. (2013) 12:1059–67. 10.1016/S1474-4422(13)70221-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229.

  KernanWNViscoliCMMakuchRWBrassLMHorwitzRI. Stratified randomization for clinical trials. J Clin Epidemiol. (1999) 52:19–26. 10.1016/S0895-4356(98)00138-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230.

  NicholsonKACudkowiczMEBerryJD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all?Neurotherapeutics. (2015) 12:376–83. 10.1007/s13311-015-0341-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231.

  MillerTMSmithRAKordasiewiczHKasparBK. Gene-targeted therapies for the central nervous system. Arch Neurol. (2008) 65:447–51. 10.1001/archneur.65.4.nnr70007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232.

  Lagier-TourenneCBaughnMRigoFSunSLiuPLiHRet al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA. (2013) 110:E4530–9. 10.1073/pnas.1318835110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233.

  RocheJCRojas-GarciaRScottKMScottonWEllisCEBurmanRet al. A proposed staging system for amyotrophic lateral sclerosis. Brain. (2012) 135(Pt 3):847–52. 10.1093/brain/awr351

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234.

  ChioAHammondERMoraGBonitoVFilippiniG. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2015) 86:38–44. 10.1136/jnnp-2013-306589

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235.

  ThakoreNJLapinBRKinzyTGPioroEP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:483–494. 10.1080/21678421.2018.1484925

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236.

  FangTAl KhleifatAStahlDRLazo La TorreCMurphyCUk-Mnd LicalSet al. Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:227–32. 10.1080/21678421.2016.1265565

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 237.

  TramacereIDalla BellaEChioAMoraGFilippiniGLauriaG. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2015) 86:1180–5. 10.1136/jnnp-2014-310176

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238.

  BraakHBrettschneiderJLudolphACLeeVMTrojanowskiJQDel TrediciK. Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat Rev Neurol. (2013) 9:708–14. 10.1038/nrneurol.2013.221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 239.

  BrettschneiderJDel TrediciKToledoJBRobinsonJLIrwinDJGrossmanMet al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. (2013) 74:20–38. 10.1002/ana.23937

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240.

  KassubekJMullerHPDel TrediciKBrettschneiderJPinkhardtEHLuleDet al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. (2014) 137(Pt 6):1733–40. 10.1093/brain/awu090

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241.

  ShermanAVGubitzAKAl-ChalabiABedlackRBerryJConwitRet al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2013) 14(Suppl. 1):53–61. 10.3109/21678421.2013.779058

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242.

  ShermanABowserRGrassoDPowerBMilliganCJaffaMet al. Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler. (2011) 12:11–6. 10.3109/17482968.2010.539233

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243.

  OttoMBowserRTurnerMBerryJBrettschneiderJConnorJet al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. (2012) 13:1–10. 10.3109/17482968.2011.627589

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244.

  TurnerMRGrosskreutzJKassubekJAbrahamsSAgostaFBenatarMet al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. (2011) 10:400–3. 10.1016/S1474-4422(11)70049-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245.

  JohnstonMVAdamsHPFatemiA. Neurobiology of Disease. Oxford: Oxford University Press (2016).

  • Google Scholar

• 246.

  Northeast ALS Consortium. NEALS Member Sites. Available online at: https://www.neals.org/about-us/neals-member-sites/

  • Pubmed Abstract
  • Google Scholar

• 247.

  BeghiE. 127th ENMC International Workshop: implementation of a European registry of ALS. Naarden, The Netherlands, 8-10 October 2004. Neuromuscul Disord. (2006) 16:46–53. 10.1016/j.nmd.2005.10.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248.

  BeghiELogroscinoGChioAHardimanOMitchellDSwinglerRet al. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta. (2006) 1762:1150–7. 10.1016/j.bbadis.2006.09.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249.

  HobsonEVBairdWOPartridgeRCooperCLMawsonSQuinnAet al. The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:351–61. 10.1080/21678421.2018.1440408

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 250.

  GeronimoAWrightCMorrisAWalshSSnyderBSimmonsZ. Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:555–61. 10.1080/21678421.2017.1338298

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251.

  ChristodoulouGGenningsCHupfJFactor-LitvakPMurphyJGoetzRRet al. Telephone based cognitive-behavioral screening for frontotemporal changes in patients with amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:482–8. 10.3109/21678421.2016.1173703

  • Pubmed Abstract
  • CrossRef
  • Google Scholar